These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30524542)

  • 1. Non-traumatic splenic rupture on dual antiplatelet therapy with aspirin and ticagrelor after stenting for acute coronary syndrome.
    Grifoni E; Paniccia R; Giusti B; Sticchi E; Padeletti L; Cavallini C; Marcucci R
    J Cardiol Cases; 2015 Sep; 12(3):65-67. PubMed ID: 30524542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience.
    Cecchi E; Marcucci R; Chiostri M; Mecarocci V; Spini V; Innocenti L; Calabretta R; Cordisco A; Romano SM; Abbate R; Gensini GF; Giglioli C
    Intern Emerg Med; 2015 Oct; 10(7):805-14. PubMed ID: 25944129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
    Chyrchel B; Totoń-Żurańska J; Kruszelnicka O; Chyrchel M; Mielecki W; Kołton-Wróż M; Wołkow P; Surdacki A
    Platelets; 2015; 26(6):593-7. PubMed ID: 25350775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case report of atraumatic splenic rupture after coronary stenting and dual antiplatelet therapy: Causality or relationship?
    Boccanelli P; Materazzo M; Venditti D; Pellicciaro M; Santori F; Grande M
    Int J Surg Case Rep; 2021 Nov; 88():106578. PubMed ID: 34758435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Tonon F; Kedhi E; Suryapranata H; Carriero A; De Luca G;
    J Thromb Thrombolysis; 2019 Oct; 48(3):413-421. PubMed ID: 31065927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
    Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C
    Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Jiang Z; Zhang R; Sun M; Liu Q; Wang S; Wang W; Zhao Q; Zhang H; Wang Y; Hou J; Yu B
    Can J Cardiol; 2018 Dec; 34(12):1606-1612. PubMed ID: 30527148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
    Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
    Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.